Unbiased AI-powered news
Japan's Upper House approved legislation on Friday to increase patient co-payments for roughly 1,100 prescription medicines that have ingredients and effects similar to over-the-counter drugs. The same bill also expands public health insurance coverage to include all childbirth-related costs.
The Japan TimesJapan's Upper House passed legislation on Friday that will raise co-payments for certain prescription medicines starting in March 2027. The measure targets about 1,100 drugs whose ingredients and effects are similar to over-the-counter products. The bill reforms the national healthcare insurance system and aims to limit future increases in insurance premiums paid by the working population.
It passed by majority vote during the chamber's plenary session.
The legislation also places all costs associated with childbirth under public health insurance. Standard deliveries are currently excluded from coverage. Women who give birth now receive a one-time allowance of ¥500,000 ($3,130) per child. The bill states that actual hospital delivery costs vary, and the fixed payment is often insufficient to cover expenses.
The health ministry plans to implement the higher co-payments for the identified medicines in March 2027.
Single source — no framing comparison available.
washingtonpost.comFlooding along the Guadalupe River has killed at least one person in central Texas. The same area recorded more than 130 deaths in flash floods last summer. Governor Greg Abbott confirmed the fatality in a Thursday update.
upi.comThe Food and Drug Administration approved enlicitide, sold as Lipfendra, on Thursday. Manufactured by Merck, the pill inhibits PCSK9 and cut LDL levels by up to 60 percent in a 24-week trial of 2,912 participants. It carries a list price of $315 for a 30-day supply and will reach…
flipboard.comEli Lilly will pay $2.8 billion in cash to acquire AtaiBeckley, a developer of psychedelic treatments for mental health conditions. The deal includes up to $1 billion in additional milestone payments. It adds the target’s compounds to Lilly’s neuroscience programs.